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Recurrence Rate After a First Venous Thrombosis in
Patients With Familial Thrombophilia
Carla Y. Vossen, Isobel D. Walker, Peter Svensson, Juan C. Souto, Inge Scharrer, F. Eric Preston,
Gualtiero Palareti, Ingrid Pabinger, Felix J.M. van der Meer, Mike Makris, Jordi Fontcuberta,
Jacqueline Conard, Frits R. Rosendaal
Objective—Few comprehensive data are available on the recurrence rate of venous thrombosis in carriers of thrombophilic
defects from thrombophilic families. We prospectively determined the recurrence rate after a first venous thrombotic
event in patients with familial thrombophilia attributable to factor V Leiden or deficiencies of protein C, S, or
antithrombin.
Methods and Results—Data were gathered during follow-up on the occurrence of risk situations, anticoagulation
treatment, and events (eg, venous thrombosis, hemorrhage). Over a mean follow-up period of 5.6 years, 44 of the 180
patients with familial thrombophilia who did not use long-term anticoagulation experienced a recurrent venous
thromboembolic event (5.0%/year; 95% CI 3.6 to 6.7) compared with 7 of the 124 patients on long-term anticoagulation
(1.1%/year; 95% CI 0.4 to 2.2). Spontaneous events occurred less often in patients on long-term anticoagulation (57%)
than in patients without long-term anticoagulation (75%). The highest recurrence rate was found among men with a
deficiency in natural anticoagulants or multiple defects and women with antithrombin deficiency. Although long-term
anticoagulation treatment decreased the incidence of recurrent events by 80%, it also resulted in a risk of major
hemorrhage of 0.8% per year.
Conclusions—Extra care after a first event is required for men with a deficiency in natural anticoagulants or multiple
defects and women with antithrombin deficiency. (Arterioscler Thromb Vasc Biol. 2005;25:1992-1997.)
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Aprior history of venous thrombosis is a strong predictorfor venous thrombosis, with recurrences in 3% to 13%
of consecutive patients after 1 year and 12% to 28% after 5
years.1–6 Patients with a first venous thrombotic event will
receive oral anticoagulant treatment for at least 3 months after
a deep vein thrombosis (6 months when the event was
idiopathic) and at least 6 months after a pulmonary embolism.
Decisions on extending anticoagulant treatment are based on
the perceived risks of venous thromboembolism recurrence
and anticoagulant-related bleeding. Whether long-term con-
tinuation of anticoagulant treatment should be considered
after a first venous event in carriers of a thrombophilic defect
from thrombophilic families is still uncertain, as few com-
prehensive data are available on whether inherited risk factors
increase the risk of recurrence. As was shown by us previ-
ously, it is important to distinguish between unselected
patients with a thrombophilic defect and individuals from
thrombophilic families, as the latter tend to have a much
higher risk probably attributable to the concomitant presence
of other risk factors within these families.7,8 To our knowl-
edge, only 2 studies described the recurrence risk associated
with familial deficiencies of protein C, protein S, and anti-
thrombin: Pabinger et al found a high recurrence rate of 63%
for patients with familial deficiencies of natural anticoagulant
factors,9 and annual incidences calculated on available liter-
ature by Van den Belt et al ranged from 13% to 17% for
patients with familial antithrombin deficiency and from 14%
to 16% for patients with familial protein S deficiency.10 In the
same article by Van den Belt et al, the results of a retrospec-
tive cohort study revealed a cumulative incidence of 10%
after 1 year and 23% after 5 years for patients with inherited
antithrombin-, protein S-, or protein C deficiency.10 For factor
V Leiden contradicting results have been published about the
risk of recurrent venous thrombosis.6,11–15 To our knowledge
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only 1 study focused on patients with a positive family
history and concluded that the incidence of recurrent venous
events depends on the presence of other thrombophilic
disorders.16
We started the European Prospective Cohort on Thrombo-
philia (EPCOT-) study, a large prospective cohort study of
individuals with familial thrombophilia, to obtain reliable risk
estimates of the absolute risk of venous thrombosis in
families with inherited thrombophilia. The aim of the current
analysis was to determine the recurrence risk for participants
with a hereditary thrombophilic defect and a history of one
venous thromboembolic event before study entry. We fo-
cused on selected families with a clear thrombotic tendency,
and the results could assist physicians in decisions on testing
for thrombophilic abnormalities and choices about long-term
anticoagulation after a first thrombosis.
Methods
As previously described,17 participants from 8 European countries
were included between March 1994 and September 1997. Follow-up
was until January 2001. The defects of interest were deficiencies of
antithrombin, protein C, protein S, or factor V Leiden. We gathered
information on the prothrombin G20210A variant as a second defect
for 207 of the 304 patients (68%). The analysis includes only patients
with 1 objectively confirmed deep venous thrombosis (DVT) or
pulmonary embolism (PE) before inclusion in the study. For all
patients, we calculated the absolute risk (incidence) and 95%
confidence intervals18 of recurrent venous thrombosis and severe
hemorrhage during follow-up. We calculated the recurrent event-free
survival according to the number of observation years using the
Kurtzke method.19 To determine the benefit of long-term anticoag-
ulation, we calculated the relative risk of venous thrombosis by
Cox-regression with and without adjustment for regional (center),
age, and sex effects. (Please see http://atvb.ahajournals.org for a
detailed method section.)
Results
Prospective data were collected on 304 patients with a history
of 1 objectively confirmed DVT or PE before inclusion in the
follow-up study. Of these subjects, 124 patients (69 probands
and 55 relatives) were classified as being on long-term
anticoagulation during prospective follow-up, while 180 pa-
tients (139 probands and 41 relatives) were not on long-term
prophylactic anticoagulation. The total prospective follow-up
time of the 304 patients was 1710 years (mean 5.6; range 1 to
7 years). During follow-up, 6 patients were lost-to-follow-up
and 6 patients died as a result of heart disease (n2), cancer
(n2), septic shock (n1), and pneumonia (n1).
Table 1 depicts the main characteristics at inclusion of the
patients. Among those not on long-term anticoagulation,
there were relatively fewer men and more probands than
among those who received long-term anticoagulation. The
latter can be explained by a low frequency of long-term
anticoagulation among probands with factor V Leiden.
Recurrence Rates
Of the 180 patients who did not receive long-term anticoag-
ulant treatment during prospective follow-up, 44 (24%)
experienced a recurrent thrombotic event (Table 2) compared
with 7 of the 124 (6%) patients on long-term anticoagulant
treatment (Table 3). Of the patients who did not receive
long-term anticoagulant treatment, 4 used aspirin and 2 used
heparin (short-term during surgery and pregnancy) at the time
of the event. Thirty-three of the 44 events (75%) in those not
on long-term anticoagulation occurred spontaneously, and the
11 remaining events occurred after traveling for more than 8
hours (n5), during pregnancy (n3), and after surgery
(n3). Of the women who experienced a recurrent event
during pregnancy, 2 had received no prophylaxis during
pregnancy and 1 had received low molecular weight heparin
TABLE 1. General Characteristics of the Thrombophilic
Subjects With 1 Confirmed DVT or PE at Study Entry
Patients (n304)
No Long-Term
Anticoagulation
Long-Term
Anticoagulation
All, n 180 124
Men, n (%) 63 (35) 59 (48)
Probands, n (%) 139 (77) 69 (56)
Age at inclusion, mean years (range) 39 (14–78) 41 (20–72)
Age at 1st event, mean years (range) 32 (11–70) 33 (13–71)
Type of thrombophilia
PC deficiency, n 37 32
PS deficiency, n 25 30
AT deficiency, n 11 26
FVL, n 79 (12 AA) 13 (4 AA)
Combined defects, n 28 23
PC-PS 0 1
PC-FVL 6 7
PC-PT 3 4
PC-FVL-PT 2 0
PS-FVL 4 4
PS-PT 2 2
AT-FVL 2 3
AT-PT 2 1
FVL-PT 7 1‡
Risk factors
BMI, mean kg/m2 (range) 25 (17–47) 25 (17–34)
Cancer ever, % 2 0
Arterial disease, % 3 9
Thrombosis history
DVT, n (%) 133 (74) 79 (64)
PE, n (%)* 47 (26) 45 (36)
Spontaneous DVT or PE, n (%)† 105 (58) 62 (50)
History of STPs, n (%) 37 (21) 40 (32)
Time between 1st event and
study entry, mean years (range)
6.4 (0–38) 7.3 (0–33)
PC indicates protein C deficiency; PS, protein S deficiency; AT, antithrombin
deficiency; FVL, factor V Leiden; AA, homozygotes for factor V Leiden; PT,
prothrombin G20210A; BMI, body mass index; DVT, deep venous thrombosis;
PE, pulmonary embolism; STP, superficial thrombophlebitis.
*A DVT and PE were experienced at the same time by 29 patients without
and 29 patients with long-term anticoagulation.
†Defined at entry as events in the absence of the following risk situations:
surgery, cancer, hospitalization, plaster cast, immobilization, pregnancy, and
traveling.
‡One was homozygous for FVL.
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(LMWH) daily from week 6 to 37 with an event around week
11 of the pregnancy. Of the 3 individuals with a recurrent
event after surgery, 2 had received no prophylaxis during foot
surgery and surgery for breast cancer, whereas 1 was consid-
ered to have had adequate prophylaxis. Of the patients on
long-term anticoagulation, 4 of the 7 events (57%) occurred
spontaneously (3 had their last international normalized ratio
[INR] within the desired range of 2 to 3, whereas one patient
used anticoagulation irregularly despite the prescription), 2
events occurred during or after pregnancy (with LMWH
prophylaxis daily), and 1 individual who received adequate
anticoagulation treatment experienced an event after strenu-
ous exercise (karate). Thirteen of the 180 patients (7%) who
did not use long-term anticoagulation experienced a superfi-
cial thrombophlebitic event during prospective follow-up (ie,
as the only venous recurrent event or before a recurrent DVT
or PE) compared with 9 of the 124 patients (7%) on long-term
anticoagulation.
The recurrence rate was 5.0% per year (95% CI 3.6 to 6.7)
in patients who were not on long-term anticoagulation and
1.1% per year (95% CI 0.4 to 2.2) in those on long-term
anticoagulation (Tables 2 and 3). Thus, the risk of recurrent
events was 80% lower in the patients on long-term anticoag-
ulation treatment (crude relative risk 0.2; 95% CI 0.1 to 0.4;
unchanged when adjusted for center, sex, and age at inclu-
sion). In patients who did not receive long-term anticoagula-
tion treatment, the recurrence rate was much higher among
men (9.6%/year; 95% CI 6.3 to 13.9) than among women
(2.8%/year; 95% CI 1.7 to 4.5) (Table 2) with a relative risk
of 3.0 (95% CI 1.6 to 5.6), which remained unchanged when
adjusted for age (relative risk 3.1; 95% CI 1.6 to 5.9) or when
we restricted the analysis to those with a first spontaneous
venous thrombotic event (relative risk 3.1; 95% CI 1.4 to
7.1). Among the thrombophilic women who were not on
long-term anticoagulation, measures to reduce the risk of
recurrence associated with pregnancy or use of female hor-
mones were frequently used: 25 of the 29 (86%) women who
were pregnant during prospective follow-up received throm-
boprophylaxis during pregnancy or puerperium, and only 13
of the 100 (13%) women between the age of 15 and 50 used
oral contraceptives, of whom 9 women used oral contracep-
tives which contained no estrogen. Among the thrombophilic
TABLE 3. Incidence Rates (%/year) of a Recurrent DVT or PE in Patients on
Long-Term Anticoagulant Treatment During Prospective Follow-Up
Patients n
Time Between 1st
Event and Study Entry,
Mean Years (Range)
DVT/PE,
n
Person
Years, n
Incidence Rate,
%/Year (95% CI)
All patients 124 7.5 (0–36) 7* 652.0† 1.1 (0.4–2.2)
PC deficiency 32 6.7 (0–29) 1 172.1 0.6 (0.0–3.2)
PS deficiency 30 6.2 (0–20) 1 172.8 0.6 (0.0–3.2)
AT deficiency 26‡ 6.7 (0–26) 4 146.9 2.7 (0.7–7.0)
FVL 13 7.3 (1–24) 0 43.4 0.0 (0.0–8.5)
Multiple defects 23 11.2 (0–36) 1§ 116.8 0.9 (0.0–4.8)
DVT indicates deep venous thrombosis; PE, pulmonary embolism; PC, protein C; PS, protein S; AT,
antithrombin; FVL, factor V Leiden; CI, confidence interval.
*Five patients experienced a DVT, 1 a PE, and 1 a cerebral venous event.
†The follow-up time regardless of treatment was 687.3 years. None of the individuals received
treatment for less than a year.
‡One individual received antithrombin concentrate as anticoagulation therapy.
§This individual was protein S deficient and factor V Leiden carrier.
TABLE 2. Incidence Rates (%/year) of a Recurrent DVT or PE in Patients Who Did Not Receive Long-Term Anticoagulant
Treatment During Prospective Follow-Up
Patients n
Time Between 1st
Event and Study Entry,
Mean Years (Range)
DVT/PE,
n
Person Years,
n
Incidence Rate,
%/Year (95% CI)
Incidence Rate Men,
%/Year (95% CI)
Incidence Rate Women,
%/Year (95% CI)
All 180 6.4 (0–38) 44* 881.7 5.0 (3.6–6.7) 9.6 (6.3–13.9) 2.8 (1.7–4.5)
PC deficiency 37 6.3 (0–27) 10 195.0 5.1 (2.5–9.4) 10.8 (4.0–23.4) 2.9 (0.8–7.4)
PS deficiency 25 5.3 (0–16) 8 122.4 6.5 (2.8–11.8) 10.5 (3.9–22.9) 3.1 (0.4–11.0)
AT deficiency 11 9.3 (1–24) 6 57.4 10.5 (3.8–22.8) 11.6 (2.4–33.9) 9.5 (2.0–27.8)
FVL 79 5.3 (0–38) 13 (1 AA) 366.3 3.5 (1.9–6.1) 7.2 (2.9–14.9) 2.2 (0.8–4.8)
Multiple defects 28 9.4 (1–30) 7† 140.6 5.0 (2.0–10.3) 10.7 (3.5–24.9) 2.1 (0.3–7.7)
DVT indicates deep venous thrombosis; PE, pulmonary embolism; PC, protein C; PS, protein S; AT, antithrombin; FVL, factor V Leiden; AA,
homozygotes for factor V Leiden; CI, confidence interval.
*Thirty-four experienced a DVT, 6 a PE, and 4 a DVT and PE concurrently.
†Three with protein C deficiency and factor V Leiden, 1 with protein C deficiency and the prothrombin 20210A variant, 1 with factor V Leiden and
the prothrombin 20210A variant, 1 with protein C deficiency, factor V Leiden and the prothrombin 20210A variant, and 1 with antithrombin deficiency
and the prothrombin 20210A variant.
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women who were on long-term anticoagulation, 10 of the 50
(20%) women between the age of 15 and 50 used oral
contraceptives, of whom 9 women used estrogen-containing
oral contraceptives.
The lowest recurrence rates, although the confidence inter-
vals were wide, were found in patients with factor V Leiden
(3.5%/year without and 0.0%/year with long-term treatment),
and the highest recurrence rates were found in patients with
antithrombin deficiency (10.5%/year without and 2.7%/year
with long-term treatment) (Tables 2 and 3). However, when
we calculated the incidences for men and women separately,
we found among those not on long-term anticoagulation high
and similar recurrence rates for men with protein C, protein S,
or antithrombin deficiency and men with multiple defects
(10.5 to 11.6%/year; Table 2). For men with factor V Leiden
we found a lower rate (7.2%/year; Table 2). For women,
except for those with antithrombin deficiency (9.5%/year),
the recurrence rates were much lower (2.1 to 3.1%/year;
Table 2).
Besides a difference in the recurrence rate among men and
women who received no long-term anticoagulation, we
found, although confidence intervals were wide, a higher
recurrence rate in the probands, and in the patients with a
spontaneous first event than in the other patients. The annual
incidence of spontaneous events per type of defect was 6.9%
(95% CI 2.8 to 14.3) for protein C deficiency, 8.9% (95% CI
2.9 to 20.9) for protein S deficiency, 9.3% (95% CI 1.9 to
27.1) for antithrombin deficiency, 3.6% (95% CI 1.7 to 6.9)
for factor V Leiden, and 7.4% (95% CI 2.4 to 17.2) for
combined defects. Among the 105 individuals with a spon-
taneous first venous thrombotic event, a recurrent event
occurred mostly also spontaneously (23/29; 79%) or during
traveling for more than 8 hours (4/29; 14%). We also found
a higher risk among those with a concurrent DVT and PE as
first event (Table 4). Of the recurrent events in those with a
concurrent DVT and PE as a first event (n12), most second
events were a DVT (n10) and 2 second events were a
concurrent DVT and PE again. Of the individuals without
long-term treatment with a DVT as first event (n133), 23
experienced a DVT (82%) as recurrent event, 3 a PE, and 2 a
concurrent DVT and PE. Of individuals without long-term
treatment with a PE as first event (n18), 1 had a DVT as
second event and 3 (75%) a PE. Although we can offer no
explanation for these observations, they are in line with
previous publications of different risk factors for DVT and
PE.20,21
In patients on long-term anticoagulation, the overall recur-
rence rates were independent of sex (recurrence rates of
1.0%/year for men and 1.2%/year for women) and the
etiology of the first event (spontaneous or not; Table 4).
However, in those on long-term anticoagulation with anti-
thrombin deficiency all recurrences occurred in women (in-
cidence 5.1%; 95% CI 1.4 to 12.9; 2 DVTs during pregnancy
for which they received LMWH, 1 spontaneous DVT and 1
spontaneous cerebral sinus thrombosis), whereas the remain-
ing 3 events in the group on long-term anticoagulation with
other defects occurred in men.
The influence of risk situations on the risk of venous
thrombosis was difficult to determine as short-term prophy-
laxis was prescribed frequently in patients who were not on
long-term anticoagulation: in 6 of the 11 individuals wearing
a plaster cast, in 7 of the 83 patients who traveled, and in 39
of the 71 patients undergoing surgery or hospitalization.
The Figure shows the recurrence-free survival curve ac-
cording to the number of observation years. For the subjects
who were not on long-term anticoagulation, five individuals
were included in the same year as their first event occurred,
and 28 individuals entered the study in 1994 or 1995 and had
experienced their first event in, respectively, 1993 or 1994.
After 2 years of observation, these 5 and 28 individuals were
followed prospectively for, respectively, 2 years and 1 year,
and 12% of these 33 individuals had experienced a recurrent
event (Figure). After 5 years of observation, an additional
10% of the subjects had experienced an event (Figure).
Recurrence-free survival was higher for subjects who were on
long-term anticoagulation: after 2 years of observation, 7 and
11 individuals were followed prospectively for, respectively,
2 years and 1 year, and 6% of these 18 individuals had
experienced a recurrent event (Figure). After 5 years of
observation, no additional subjects had experienced an event
(Figure)
Percentage of individuals who were free of a recurrent venous
event according to the number of years after a first event (cal-
culated using the Kurtzke method).
TABLE 4. Incidence Rates (%/Year) in Subgroups
Incidence, %/Year (95% CI)
No Long-Term
Anticoagulation
(n180)
Long-Term
Anticoagulation*
(n124)
Probands 5.6 (4.0–7.7) 1.4 (0.5–3.3)
Relatives 3.1 (1.3–6.5) 0.7 (0.1–2.4)
History spontaneous events 5.7 (3.8–8.2) 1.2 (0.3–3.2)
No history spontaneous events 4.0 (2.2–6.6) 0.9 (0.2–2.7)
History of concurrent DVT/PE 8.5 (4.4–14.8) 1.1 (0.1–4.1)
History of DVT or PE only 4.3 (3.0–6.1) 1.0 (0.3–2.4)
CI indicates confidence interval; DVT, deep venous thrombosis; PE, pulmo-
nary embolism.
*Incidence was in percentage per year on thromboprophylaxis.
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Risk from Prophylactic Anticoagulation
Two women who did not use long-term anticoagulation
experienced a severe hemorrhage during delivery while
receiving short-term heparin treatment to prevent thrombosis
during pregnancy. Five patients experienced a severe hemor-
rhage during the use of long-term anticoagulation (3 gastro-
intestinal hemorrhages and 2 postoperative bleeding episodes
after a hysterectomy or a thrombectomy) requiring hospital
admission for an emergency diagnosis or for treatment. One
additional patient experienced a postoperative hemorrhage
after the removal of a melanoma but had stopped oral
anticoagulation 2 weeks before during treatment with peni-
cillin for erysipelas. The incidence of severe hemorrhages
associated with the use of oral anticoagulation was 0.8% per
year (95% CI 0.3 to 1.8; 5 events on 638 years of
anticoagulation).
Discussion
In patients with familial thrombophilia, the recurrence rate of
venous thrombosis after a first DVT or PE was 5.0% per year
(95% CI 3.6 to 6.7) in the 180 patients who did not receive
long-term anticoagulation during prospective follow-up. The
recurrence rate of venous thrombosis was much higher in
men than in women with a relative risk, adjusted for age, of
3.1 (95% CI 1.6 to 5.9), which is in accordance with a recent
article by Kyrle et al who reported a relative risk of
recurrence of 3.6 (95% CI 2.3 to 5.5) for men compared with
women.22 The lower risk in women may be partly explained
by more extensive preventive measures in women, which
included frequent use of anticoagulant prophylaxis during
pregnancy and avoidance of estrogen-containing oral contra-
ceptives. A similar sex difference has been observed in
nonthrombophilic patients followed after a first venous
thrombosis.6,23 The incidence was also high for patients in
whom the first event had been a spontaneous event, as
previously reported by others.24–26 In addition, we found a
higher recurrence rate in patients who had experienced a
DVT and PE concurrently as a first event than in those with
a DVT or PE as first event. For factor V Leiden carriers the
recurrence rate (3.5% per year) was similar to the incidences
found in several prospective and retrospective studies on
unselected patients with factor V Leiden of 5% per
year.6,11–14 The risk of a recurrent event in unselected patients
with a first thrombotic event is reported to be highest in the
first year after a first event (3% to 13% after 1 year compared
with 12% to 28% after 5 years).1–6 However, as most
symptomatic individuals in the present study did not enter the
study in the same year as they had experienced their first
event, our rates cannot readily be compared with these rates
found in other studies. When we took the year of a first event
into account, we found that 12% of the subjects who did not
receive long-term anticoagulation had experienced a recur-
rent event after 2 years. After 5 years of observation, an
additional 10% had experienced a recurrent event. We did not
include individuals with a nonobjectively confirmed recurrent
venous event only; however, these were few (n4).
The recurrence rate was 80% lower in the 124 patients
using long-term anticoagulation treatment with an incidence
of recurrent events of 1.1% per year (95% CI 0.4 to 2.2). De
Stefano et al found a low annual incidence of 1.4% for
individuals with antithrombin-, protein S-, or protein C
deficiency in a retrospective study in which most individuals
received life-long prophylaxis.27 Their finding is similar to
the recurrence rate found in the present study for patients with
protein C-, protein S-, or antithrombin deficiency receiving
long-term anticoagulation (1.2%/year; 95% CI 0.4 to 2.7),
although the recurrence rate for antithrombin deficiency
remained high (2.7% per year). The reduction of the recur-
rence rate with 80% was offset by a risk of severe hemor-
rhages during use of long-term anticoagulation of 0.8% per
year (95% CI 0.3 to 1.8), which is similar to the incidence of
major hemorrhages of 1% to 3% found in other studies.28,29
The strength of our study is its size attributable to the
collaboration of several European thrombosis centers, which
made the restriction to patients with 1 venous thrombotic
event possible. However, because this study was an observa-
tional study and not randomized, incomparability between the
groups of patients who did and did not receive long-term
anticoagulation cannot be ruled out. It is difficult to imagine,
however, how selective prescription would have led to the
overestimation of the effect of anticoagulation. This study
therefore demonstrates that long-term anticoagulation is ef-
fective in reducing the risk of recurrent thrombosis in patients
with familial thrombophilia, except in women with anti-
thrombin deficiency, who still showed a high recurrence rate
of 5.1% with long-term anticoagulation after the first event.
Although randomized studies may still be desirable to dem-
onstrate the efficacy of long-term anticoagulant treatment of
thrombophilic patients, the low prevalence of familial throm-
bophilia may render this infeasible. In addition, the overall
risk of recurrence was similar to the risk found in consecutive
patients with a first venous thrombosis who generally do not
receive long-term anticoagulation to prevent a recurrent
event, because of the risk of major hemorrhage. Therefore,
for most patients with familial thrombophilia, especially
patients with factor V Leiden, there seems to be little
justification for long-term treatment after a first event, al-
though the availability of anticoagulants with a better risk–
benefit profile could change the balance. The highest recur-
rence rates were found among men with a deficiency in
natural anticoagulants or multiple defects and women with
antithrombin deficiency. As a substantial proportion of recur-
rent events occurred during risk situations, efforts could be
aimed at preventing these secondary events.
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